# Open-label Extension Study of Brazikumab in Crohn's Disease

> **NCT03961815** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 18 (actual)

## Conditions studied

- Crohn's Disease
- IBD

## Interventions

- **DRUG:** Brazikumab Induction Dose
- **DRUG:** Brazikumab Maintenance Dose

## Key facts

- **NCT ID:** NCT03961815
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-06
- **Primary completion:** 2023-09-19
- **Final completion:** 2023-09-19
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03961815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03961815, "Open-label Extension Study of Brazikumab in Crohn's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03961815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*